Articles by Daniel Marsh
Ambev ADRs Surge 3.5% on Brazilian Market Rally
Ambev ADRs climbed 3.5% on a broad Brazilian market rally, with the real's strength driving most gains. Q2 results showed solid growth, but analyst targets imply modest upside.
India Q1 GDP Beats Forecast But Oil Prices Cap Market Gains
India's GDP grew 7.8% in Q1, beating forecasts, but oil prices near $95 limited equity gains. Special FX inflows of $136.4B provided a buffer.
Vodafone Launches TV Service to Counter Mobile Subscriber Decline
Vodafone (VOD) unveiled a new TV bundle to combat a 73,000 drop in mobile contracts, while shares rose 2.2%. The service launches in October with 200+ channels and streaming apps.
Long-Dated UK Yields Steady Near Heights as Fiscal Worries Persist
UK 30-year gilt yields remain near record highs as fiscal and inflation worries persist. The 10-year yield surpasses year-end survey projections, with BoE meeting and budget due.
Opendoor Gains 1.6% as Inventory Swells to $1.85B Amid Rate Uncertainty
Opendoor (NASDAQ:OPEN) gained 1.6% to $3.09 as its $1.85 billion inventory underscores interest-rate exposure. Q2 purchases surged 149% while sales fell 46%.
Air Canada Shares Dip Below Buyback Floor as Jazz Crews Vote on Strike
Air Canada shares slipped below its buyback threshold as Jazz Aviation flight attendants vote on a strike mandate, threatening regional operations.
CNH Surges 9% on Upgrade, Farm Rebound Seen by 2027
CNH Industrial shares surged 9.2% after Evercore ISI upgraded the stock and raised its price target to $18, citing an anticipated farm equipment rebound by 2027.
IREN Climbs 7.6% as $3B AI Contract Revenue Awaits Activation
IREN shares jumped 7.6% to $39.60, recovering most of last week's post-results slide, but $3 billion of contracted AI ARR remains unactivated, keeping valuation stretched.
Ultragenyx Plunges 44% as Angelman Gene Therapy Fails Phase 3 Trial
Ultragenyx's stock plummeted 44% after its Phase 3 apazunersen trial failed, wiping out $1.14 billion in market cap. The company now faces major cost cuts.
PG&E Shares Tumble 5% on $2B Capex Cut Amid Regulatory Uncertainty
PG&E shares dropped 5.2% after the utility postponed $2 billion in 2027 capital spending, citing financing costs and regulatory uncertainty. The company reaffirmed 2026 guidance but trimmed expansion plans.